Should You Buy Mineralys Therapeutics Inc (MLYS) Today? Analysis, Price Targets, and 2026 Outlook.
Analysis Updated At
2026/01/30
BUY now (speculative biotech). With MLYS trading pre-market around 32.31—just below the 32.69 pivot and close to support (31.29)—the setup offers a reasonably defined entry level for an impatient buyer. While near-term technical momentum is not strong and options positioning skews defensive (puts > calls), Wall Street remains consistently bullish (multiple Buy ratings with raised targets), and hedge funds are accumulating aggressively. Net: I would buy here rather than wait, using 31.29 as the key line that should hold for the thesis to remain intact.
**Intellectia Proprietary Trading Signals**
- [AI Stock Picker](module://ai_stock_pick): No signal on given stock today.
- [SwingMax](module://swingmax): No signal on given stock recently.
Technical Analysis
Price is consolidating near a key decision area: pre-market ~32.31 versus Pivot 32.694. Support levels sit at S1 31.285 and S2 30.414; resistance is R1 34.104 then R2 34.975.
- Momentum: MACD histogram is positive (0.122) but positively contracting, implying bullish momentum exists but is fading.
- RSI(6) ~40.16: mild weakness/soft demand, not oversold, not a clear reversal signal.
- Moving averages: converging, consistent with consolidation/range behavior rather than a clean trend.
Practical read: technically this is a “range entry near support” more than a breakout buy. A move back above the pivot improves odds of testing 34.10; losing 31.29 increases risk of a drop toward ~30.41. Pattern-based stats provided suggest modest downside over the next week (-1.4%) but favorable 1-month odds (+14.41%).
Analyst Ratings and Price Target Trends
Recent Street trend is clearly positive: all cited notes are Buy reiterations with price-target raises.
- 2025-12-19 Stifel: PT raised to 52 from 45, Buy.
- 2025-12-19 BofA: PT raised to 46 from 43, Buy; highlights partnering as a major catalyst and ‘necessary to maximize value’.
- 2025-11-12 H.C. Wainwright: PT raised to 56 from 52, Buy; upbeat on trajectory toward application submission.
Wall Street pros: strong upside targets, catalyst path via partnering + regulatory progress, runway into 2027. Cons: execution risk and dependency on partnership/regulatory milestones; continued losses with no revenue.
Wall Street analysts forecast MLYS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MLYS is 52.6 USD with a low forecast of 46 USD and a high forecast of 56 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Wall Street analysts forecast MLYS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MLYS is 52.6 USD with a low forecast of 46 USD and a high forecast of 56 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Current: 32.090
Current: 32.090
